{"name":"Lambda Therapeutic Research Ltd.","slug":"lambda-therapeutic-research-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Denosumab-Ref","genericName":"Denosumab-Ref","slug":"denosumab-ref","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"phase_3"}]}],"pipeline":[{"name":"Denosumab-Ref","genericName":"Denosumab-Ref","slug":"denosumab-ref","phase":"phase_3","mechanism":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), preventing osteoclast formation and bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of osteoporosis in postmenopausal women and men at high risk of fracture"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPRF9tOU1Oc2VoTjRxX21JdFh1VzJPRFI0V1JiZTRjWG5sY0xsNkV1dGlXSTJfQ0MyV3pnRllZT095YnBoQUpsVDdSTHZpWEZSRDFQc0Eza3FJLTB4OEFHS1ZrRWxoZloyeGVxX29aX3pBeHU4Szh6NnBjbElubEZlSHlnd3BwWnZzVHc0cWlXRWc2emc4WUpDc3oyeThRbzNxaE5sVUZZel9HSnFXVFVSVTZqYjgwWDNOS0w5UlZ6OHVEQ0oyWjNpWXNlY3ZzbW1KZFk0ODNDZExlYjMwZlEtNjlpa2psUQ?oc=5","date":"2025-12-16","type":"trial","source":"scanx.trade","summary":"Syngene International Hosts Clinical Trials Market Webinar to Showcase T&CR Business Capabilities - scanx.trade","headline":"Syngene International Hosts Clinical Trials Market Webinar to Showcase T&CR Business Capabilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPeldHZHdUUHl6MkhFdlpBaFduZzZOOUh6R05FbTE3M2NUc1hWd1ZCeVFyMEN0WFBkSGdmb2wtdlhqUk9UWEFoSUVtQ0VMUkJoWnFNQmx6NTY1c3VDVjNkc19nNGRtd3VDcWFQZ3hLS2tyMFJFN0IxQXBCbC1NQWNTWkZiRndYQk1EMmtTT0hNRWZybkItSndFbEFxREpSQ0l0Mk1ZeU93WU5ITDlXbEZDcVZDTFlweFRwOVZiQjZPZlp1RXF6SERsLTAtUk5TQVdnMm9tcWw1OWpiMndtckE?oc=5","date":"2025-11-05","type":"regulatory","source":"Taxscan","summary":"CESTAT Finds Factual Error in Denial of Duty Exemption on Imported Clinical Trial Drugs, Remands Matter [Read Order] - Taxscan","headline":"CESTAT Finds Factual Error in Denial of Duty Exemption on Imported Clinical Trial Drugs, Remands Matter [Read Order]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOd3Q5aUJ2dTlQZlVQM3RWQ0RqV2VyQTMzcTVrN3EzSzhyNlZ3Njh6TEdOZVBycEwzX1l6UFRwSklaMWc0ZjZlWnRySVhYdzdwLTZQaE81U1NlQnZNNWRZT0FtUnJ5VXREdXg4M3Iza3JzYnVHTGNqRXdkWUJvZkRSVno0cDV2bUd0ZGdsOTNSWkhXQdIBlwFBVV95cUxNazBjVGxVRGtrdVRBZlRNSjNRWXZjdDg4WEFxSU0wRTI0U3lxTnNQXy1YbHlzM0l3U3NfYXBOSjZvZHp3Y2JiX2p3Z2Z0eGVEMVJ3YXl0aDVSVXI0SzhiX0djbFk4QXEzUEptYVlUS2lVXzNfWG9WX3lsWlh4cDkybEN0dXR1dlVYanVFdC1NX2FlQTZHc1ZF?oc=5","date":"2025-09-15","type":"pipeline","source":"BioTecNika","summary":"Senior Scientist – Cell Line Development Job Role at Lambda Therapeutic Research | MSc Graduates Apply - BioTecNika","headline":"Senior Scientist – Cell Line Development Job Role at Lambda Therapeutic Research | MSc Graduates Apply","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxQanMyUkU0alBMa3VMSWE3VTZlbkpEblB0dUsyc0hkREFyNFg0TkJCX2V3bXhjVm9udWRnYlltVHU0dHVHUnRKYkNSWm9wN3k3Y1Vwb0J2R0dJR1pqR1MxSlkwNnhVOFlLYUhudFJVeFdrckRaNjZtTUc3NmNRZW41UVRkN3NNdkxfbzFQUGJETDdFNjlrbk1IajVUdUpKdDVzNGRTTEYzcjMwWVE1S0pHN1Z6ZWNqeG9mQXMwbE1MNy1ha0RNeGxZVDk4YmltMjc4Yy1mQU1GZlIwNUg1SDRTblcwS2t2WlplSmJSWU9LTkw0SjhyN3lpU05pRGhYc3NoYm54clZYSUJteUhPblFpUmxESUZEQUxvcXRYRDlUTXBYNXlLX05aeXMwbURFSXpYVVFIaEZKVnVjQUlFUmpvamxGdUZDME82UHVWSmVsZWU1UQ?oc=5","date":"2025-04-15","type":"pipeline","source":"Business Wire","summary":"OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra - Business Wire","headline":"OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Stru","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQWEQwSVYzMGFrcmdCMGx5SnlpQWdDRG1sRDJLNVl3bXFDeWU2TmE5WEx2eEZHTVBaN2hXRUs1UEhIRVhMWjNDT2NudUxuYVRfa1VYS0ltdVY2V19UREdKTjIxNmJScEJsN0ZYYVVUcGZZODNSS3YyQXl1U2VBbHFWYm5qRnlBSHFJZ0VDZmxFSUVJUQ?oc=5","date":"2024-02-09","type":"trial","source":"Frontiers","summary":"Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition - Frontiers","headline":"Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBtbEprZGIzbGliMG5JX2VZcDgwcmhEWUFMUWQ2SGFYR2VUUnYwWTJFSU9yQUJtQUdVcDMwS2NjVno0SlYyWWRmWW1HTVZ4ZFBOTWpMaTExYw?oc=5","date":"2022-07-14","type":"pipeline","source":"Market.us","summary":"Central Lab Market Size, Share, Trend, Analysis | CAGR of 6.4% - Market.us","headline":"Central Lab Market Size, Share, Trend, Analysis | CAGR of 6.4%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQX2FlNC0xekVFd3lRMXg0cDVOSW1VNm1tSldaUU9qcGVybnloRDhyYWFFQ2pGeGZZMG5WOWRIMjBleTVDd2VrcFNmTWVmVnQ2aUxqc1pIQ095ZkpxcjNSR0pTZm5CUEt5cERIazdhb1JDZXF5Ul9XeTg5Wk5adVB0MWV3Z3NHdDg?oc=5","date":"2022-04-02","type":"pipeline","source":"Microbioz India","summary":"Top 10 Indian origin, BA/BE CROs to look upon in 2022 - Microbioz India","headline":"Top 10 Indian origin, BA/BE CROs to look upon in 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUmdBYll1WnlkN0hHdFoyQlRIdi02M3ZEbml1OHVWdjluQjlaOEtpMy16SURaLTVhOTFVcm9PbXdRZW54Z0RNV0F6cFB5TkJiZXFmcGtkVDlzd0tiMkhYRElQblVWbkVidGplTlhKVHJFbHFXQ243enM5UzJhTGNOZ19vQ1lHdXY3TzJZTkxaOU9BcVJ2WGNibUZVVHJwQmRQelRDRjlpb2pydw?oc=5","date":"2020-07-22","type":"deal","source":"The Business Journals","summary":"Novum acquires Lambda Therapeutic Research lab - The Business Journals","headline":"Novum acquires Lambda Therapeutic Research lab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOVHlGeHQ1dzJMb0xDZ2xVRTRsdkh2VjljSWZBbUpVbFpBQ3VhWG16ZHZlYU9Xa3BkLVgtb05ZZWhFUG5ZUE1VTlZuRkllZFlCVy1Gb0I0bTcwUktLOXdaU1lsN1FRYk41WVR4VzIyaFV5aWtBSGJiM2ZvbkxOZjFIVWdBdmgzZEpieERnazhvbDJGcGNXWGpEY2tOUzhRZkFzM0gybktPLTdBY2M3S0o0clpsNEVHSUswVmVTdg?oc=5","date":"2020-06-05","type":"trial","source":"Oncology Nurse Advisor","summary":"Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study - Oncology Nurse Advisor","headline":"Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNNmk4V1hDSENtbXB2NlQzOG5uWTd2dFJyalBoR2p3aGYwQVBQRERPZnYwZ2VTY2F3MmJDbmxZSmE0WE5rM0FFbXpIbkphTUJQTnJBbUtPbzZ2SlJ3c2lpc3ZZSTlUTUpkZnNVNktnYzJiczFlbGg2VWdIUVpaall3azdB?oc=5","date":"2019-01-30","type":"deal","source":"VCCircle","summary":"Clinical research firm Lambda to buy US-based Novum - VCCircle","headline":"Clinical research firm Lambda to buy US-based Novum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNa2dTMktuUmtzWFJkQlQxSFpRb3NiSXVHaS1LMmRaTDNCelc3bEg2WnNVVGs5cF9FRktpRzI2TWdzVFVxTVBKUTF2c1hhUEpkUmtMbEstMkpXMGFXRmk2dlZESEh5dkJzWnNhTlFZTS04T2dqSGF0eHp5ejRXbURETVFramNSVzRIQWw2MENtbTZlbDBXRnphMnJPOTNhcmE4Zzg2dnd6Y2_SAa4BQVVfeXFMTWdMZXBpUkRfa1cwb2Njajljbk9mMUVVbmhac3E2QmpneWw1dXBWdnlnQ3oxSFpTcHNPbHZ6aGF6ZmUyY1ZOOXJHWGF0dUxERHV3d3pZdTcwT3VUcURjM1hxZVU2SVlxOU5Bdk9LQ2F5dmdPY2VUV3IyMzhzR1N5X0FpX25LQkR6S19hcEptRXdDakJhQWJna1FYVnpfajB3YmdHUjVjcVNTMm9fWFhR?oc=5","date":"2019-01-30","type":"deal","source":"Express Pharma","summary":"Lambda Therapeutic Research acquires Novum Pharmaceutical Research Services - Express Pharma","headline":"Lambda Therapeutic Research acquires Novum Pharmaceutical Research Services","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPdnNUbDZrVzN4WExkbmpadjF3SmJIUGVSb2gyT0lqX25JRnV3enFKU1Q2Nk9Gd0xXSDZqWWIzR2dZUGw1bW9JanBPZkRIREgxTGt0RHRwQTUtUWJuU2p3NW1KcTZjUl94ODdDQUJOcHpJdzg2MkFqMTMzWTdKeVNtUmZjWEtxbjhVMXZKZEpLd2Q2Sk0?oc=5","date":"2012-04-24","type":"pipeline","source":"Clinical Leader","summary":"Emerging CROs – One Step Forward And Two Steps Back - Clinical Leader","headline":"Emerging CROs – One Step Forward And Two Steps Back","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}